Agomelatine : its role in the management of major depressive disorder

Abstract: Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness; advances or delays in the circadian phase are documented in patients with major depressive disorder (MDD), bipolar disorder, and seasonal affective diso...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cardinali, Daniel Pedro, Vidal, María Florencia, Vigo, Daniel Eduardo
Formato: Artículo
Lenguaje:Inglés
Inglés
Publicado: Libertas Academica 2019
Materias:
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/1630
Aporte de:
id I33-R139123456789-1630
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
Inglés
topic TRASTORNOS DE LA CONDUCTA
DEPRESION
AGOMELATINA
RECEPTORES DE MELATONINA
ANTIDEPRESIVOS
ANSIOLITICOS
RECEPTORES
RECEPTORES DE SEROTONINA
spellingShingle TRASTORNOS DE LA CONDUCTA
DEPRESION
AGOMELATINA
RECEPTORES DE MELATONINA
ANTIDEPRESIVOS
ANSIOLITICOS
RECEPTORES
RECEPTORES DE SEROTONINA
Cardinali, Daniel Pedro
Vidal, María Florencia
Vigo, Daniel Eduardo
Agomelatine : its role in the management of major depressive disorder
topic_facet TRASTORNOS DE LA CONDUCTA
DEPRESION
AGOMELATINA
RECEPTORES DE MELATONINA
ANTIDEPRESIVOS
ANSIOLITICOS
RECEPTORES
RECEPTORES DE SEROTONINA
description Abstract: Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness; advances or delays in the circadian phase are documented in patients with major depressive disorder (MDD), bipolar disorder, and seasonal affective disorder (SAD). The disturbances in the amplitude and phase of rhythm in melatonin secretion that occur in patients with depression resemble those seen in chronobiological disorders, thus suggesting a link between disturbed melatonin secretion and depressed mood. Based on this, agomelatine, the first MT1/MT2 melatonergic agonist displaying also 5-HT2C serotonergic antagonism, has been introduced as an antidepressant. Agomelatine has been shown to be effective in several animal models of depression and anxiety and it has beneficial effects in patients with MDD, bipolar disorder, or SAD. Among agomelatine’s characteristics are a rapid onset of action and a pronounced effectiveness for correcting circadian rhythm abnormalities and improving the sleep/wake cycle. Agomelatine also improves the 3 functional dimensions of depression—emotional, cognitive, and social—thus aiding in the full recovery of patients to a normal life
format Artículo
author Cardinali, Daniel Pedro
Vidal, María Florencia
Vigo, Daniel Eduardo
author_facet Cardinali, Daniel Pedro
Vidal, María Florencia
Vigo, Daniel Eduardo
author_sort Cardinali, Daniel Pedro
title Agomelatine : its role in the management of major depressive disorder
title_short Agomelatine : its role in the management of major depressive disorder
title_full Agomelatine : its role in the management of major depressive disorder
title_fullStr Agomelatine : its role in the management of major depressive disorder
title_full_unstemmed Agomelatine : its role in the management of major depressive disorder
title_sort agomelatine : its role in the management of major depressive disorder
publisher Libertas Academica
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/1630
work_keys_str_mv AT cardinalidanielpedro agomelatineitsroleinthemanagementofmajordepressivedisorder
AT vidalmariaflorencia agomelatineitsroleinthemanagementofmajordepressivedisorder
AT vigodanieleduardo agomelatineitsroleinthemanagementofmajordepressivedisorder
bdutipo_str Repositorios
_version_ 1764820525754875906